Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2018 Nov 8. pii: haematol.2018.204792. doi: 10.3324/haematol.2018.204792. [Epub ahead of print]

2.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0135-8. [Epub ahead of print]

3.

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.

Cassaday RD, Stevenson PA, Wood BL, Becker PS, Hendrie PC, Sandmaier BM, Radich JL, Shustov AR.

Am J Hematol. 2018 Aug;93(4):546-552. doi: 10.1002/ajh.25030. Epub 2018 Jan 27.

PMID:
29318644
4.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

5.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

6.

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.

Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28. No abstract available.

PMID:
28351184
7.

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.

Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):225-230. doi: 10.1016/j.clml.2016.12.004. Epub 2017 Jan 10.

PMID:
28169156
8.

Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.

Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.

JAMA Oncol. 2015 Nov;1(8):1120-7. doi: 10.1001/jamaoncol.2015.2969.

9.

Development of a hematology/oncology ICD-10 documentation job aid.

Martin DB, Silas S, Covner A, Hendrie PC, Stewart FM.

J Natl Compr Canc Netw. 2015 Apr;13(4):435-40.

PMID:
25870380
10.

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.

Shadman M, Mawad R, Dean C, Chen TL, Shannon-Dorcy K, Sandhu V, Hendrie PC, Scott BL, Walter RB, Becker PS, Pagel JM, Estey EH.

Am J Hematol. 2015 Jun;90(6):483-6. doi: 10.1002/ajh.23981. Epub 2015 Feb 27.

11.

Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR, Estey EH.

Leukemia. 2015 Aug;29(8):1779-80. doi: 10.1038/leu.2015.23. Epub 2015 Feb 4. No abstract available.

PMID:
25650090
12.

G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.

Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.

Am J Hematol. 2015 Apr;90(4):295-300. doi: 10.1002/ajh.23927. Epub 2015 Jan 30.

13.

Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.

Tong WG, Sandhu VK, Wood BL, Hendrie PC, Becker PS, Pagel JM, Walter RB, Estey EH.

Haematologica. 2015 Mar;100(3):e97-8. doi: 10.3324/haematol.2014.118422. Epub 2014 Dec 19. No abstract available.

14.

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.

Lionberger JM, Pagel JM, Sandhu VK, Xie H, Shadman M, Mawad R, Boehm A, Dean C, Shannon-Dorcy K, Scott BL, Deeg HJ, Becker PS, Hendrie PC, Walter RB, Ostronoff F, Appelbaum FR, Estey EH.

Br J Haematol. 2014 Aug;166(3):375-81. doi: 10.1111/bjh.12905. Epub 2014 Apr 18.

15.

Are new oral anticoagulants ready for use in patients with cancer?

Hendrie PC, Garcia DA.

J Natl Compr Canc Netw. 2013 Nov;11(11):1446-9. Review.

PMID:
24225975
16.

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.

Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, Hendrie PC, Estey EH.

Haematologica. 2014 Jan;99(1):54-9. doi: 10.3324/haematol.2013.096545. Epub 2013 Oct 18.

17.

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.

Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH.

Br J Haematol. 2013 Oct;163(1):130-2. doi: 10.1111/bjh.12450. Epub 2013 Jul 6. No abstract available.

18.

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.

Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH.

Br J Haematol. 2011 Oct;155(2):182-9. doi: 10.1111/j.1365-2141.2011.08831.x. Epub 2011 Aug 18.

19.

Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors.

Hu J, Renaud G, Gomes TJ, Ferris A, Hendrie PC, Donahue RE, Hughes SH, Wolfsberg TG, Russell DW, Dunbar CE.

Mol Ther. 2008 Sep;16(9):1617-23. doi: 10.1038/mt.2008.135. Epub 2008 Jun 24. Erratum in: Mol Ther. 2008 Oct;16(10):1770.. Golmes, Theotonius [corrected to Gomes, Theotonius J].

20.

A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses.

Hendrie PC, Huo Y, Stolitenko RB, Russell DW.

Mol Ther. 2008 Mar;16(3):534-40. doi: 10.1038/sj.mt.6300398. Epub 2008 Jan 22.

21.

Gene targeting with viral vectors.

Hendrie PC, Russell DW.

Mol Ther. 2005 Jul;12(1):9-17. Review.

23.
24.

Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells.

Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mantel C, Broxmeyer HE.

Blood. 1994 Jan 1;83(1):137-45.

25.
26.

The kit receptor and its ligand, steel factor, as regulators of hemopoiesis.

Broxmeyer HE, Maze R, Miyazawa K, Carow C, Hendrie PC, Cooper S, Hangoc G, Vadhan-Raj S, Lu L.

Cancer Cells. 1991 Dec;3(12):480-7. Review.

PMID:
1726456
28.

Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e.

Hendrie PC, Miyazawa K, Yang YC, Langefeld CD, Broxmeyer HE.

Exp Hematol. 1991 Nov;19(10):1031-7.

PMID:
1717302

Supplemental Content

Loading ...
Support Center